The Ledger

ALGN

Align Technology IncHealth Careinsider_universe

Last close $168.32Nov 12, 2026

Day +0.81%

Currently held

Agent 8 — Dip Buyer (Peer-Aware)long
13 sh @ $157.24 · stop $136.32
+$144.45 unrealized
Agent 5 — Dip Buyer (Evolving)long
10 sh @ $152.34 · stop $135.92
+$160.12 unrealized

Everything we've seen

?Nov 13, 2:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 1.84% today, a meaningful but not outsized move. No news catalyst is identifiable, suggesting the move is driven by technical flow or broader market positioning rather than a fundamental event. The macro context (T10Y2Y at 2.0σ below trend, flattening curve) is marginally negative for risk/growth names like ALGN (med-tech/consumer discretionary adjacent), which could create a mild headwind. With 65 minutes remaining, there is enough time for continuation but not a wide runway. The move size is below the 2-5% threshold that would indicate high conviction institutional flow. No reversal signals are evident from the data provided, but no strong continuation catalysts are present either. Net assessment: borderline momentum case with no strong reason to fade, warranting the minimum continuation threshold.
!Nov 13, 2:40 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 1.84% today, a meaningful but not outsized move. No news catalyst is identifiable, suggesting the move is driven by technical flow or broader market positioning rather than a fundamental event. The macro context (T10Y2Y at 2.0σ below trend, flattening curve) is marginally negative for risk/growth names like ALGN (med-tech/consumer discretionary adjacent), which could create a mild headwind. With 65 minutes remaining, there is enough time for continuation but not a wide runway. The move size is below the 2-5% threshold that would indicate high conviction institutional flow. No reversal signals are evident from the data provided, but no strong continuation catalysts are present either. Net assessment: borderline momentum case with no strong reason to fade, warranting the minimum continuation threshold.
?Nov 13, 12:56 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 1.59% today, a modest but real move suggesting some positive flow. No headlines are present, so this is likely technical or sector-driven buying. The macro context (T10Y2Y at 2.0σ below 24-month trend, a flattish/slightly inverted curve) is marginally negative for growth/risk names like ALGN, which is a consumer discretionary/medtech name sensitive to economic conditions and consumer spending — a flat or inverted curve environment is not ideal tailwind. However, the move is not large enough to suggest it is overextended, and with 170 minutes remaining there is ample time for continuation. No reversal signals are explicitly present. Balancing the mild macro headwind against the existing upward momentum and time remaining, this is a borderline continuation setup — leaning slightly toward continuation given the system's asymmetric risk/reward profile, but not a high-conviction read.
!Nov 13, 12:56 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 1.59% today, a modest but real move suggesting some positive flow. No headlines are present, so this is likely technical or sector-driven buying. The macro context (T10Y2Y at 2.0σ below 24-month trend, a flattish/slightly inverted curve) is marginally negative for growth/risk names like ALGN, which is a consumer discretionary/medtech name sensitive to economic conditions and consumer spending — a flat or inverted curve environment is not ideal tailwind. However, the move is not large enough to suggest it is overextended, and with 170 minutes remaining there is ample time for continuation. No reversal signals are explicitly present. Balancing the mild macro headwind against the existing upward momentum and time remaining, this is a borderline continuation setup — leaning slightly toward continuation given the system's asymmetric risk/reward profile, but not a high-conviction read.
?Nov 13, 11:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up ~2.1% intraday with no headline catalyst, suggesting this is flow-driven rather than news-driven. The move is meaningful but not extreme — sitting at the lower end of the 2-5% conviction zone. With 275 minutes remaining (essentially a full afternoon session), there is ample time for continuation. The macro context (T10Y2Y at 2σ below trend, mild flattening) is modestly negative for risk/growth names like ALGN, which could create a slight headwind, but the spread effect is not severe enough to expect a material fade. No reversal signals are evident from the data provided. The absence of news is neutral per framework guidance. Overall, this reads as ordinary momentum with no strong reason to fade — probability sits in the 0.50-0.65 band, landing at 0.54 given the mild macro headwind for a growth/med-device name in a flattening yield environment.
!Nov 13, 11:10 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is up ~2.1% intraday with no headline catalyst, suggesting this is flow-driven rather than news-driven. The move is meaningful but not extreme — sitting at the lower end of the 2-5% conviction zone. With 275 minutes remaining (essentially a full afternoon session), there is ample time for continuation. The macro context (T10Y2Y at 2σ below trend, mild flattening) is modestly negative for risk/growth names like ALGN, which could create a slight headwind, but the spread effect is not severe enough to expect a material fade. No reversal signals are evident from the data provided. The absence of news is neutral per framework guidance. Overall, this reads as ordinary momentum with no strong reason to fade — probability sits in the 0.50-0.65 band, landing at 0.54 given the mild macro headwind for a growth/med-device name in a flattening yield environment.
?Nov 12, 3:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 25 minutes remaining until the forced close, the window for meaningful continuation is very narrow. The -2.46% move is significant and reflects real selling pressure, but at this stage of the session the dominant risk is mean reversion and position squaring rather than fresh momentum. No news catalyst is present to sustain directional flow into the close. The macro context (T10YIE at 1.7σ below trend) is modestly supportive of long-duration sensitive growth names like ALGN, which could attract dip buyers in the final minutes. With no catalyst to anchor the move and minimal time left for momentum to compound, the risk/reward of chasing the downside here is poor. Probability set below 0.5 primarily due to the very short time horizon and the absence of any confirming catalyst.
!Nov 12, 3:20 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
With only 25 minutes remaining until the forced close, the window for meaningful continuation is very narrow. The -2.46% move is significant and reflects real selling pressure, but at this stage of the session the dominant risk is mean reversion and position squaring rather than fresh momentum. No news catalyst is present to sustain directional flow into the close. The macro context (T10YIE at 1.7σ below trend) is modestly supportive of long-duration sensitive growth names like ALGN, which could attract dip buyers in the final minutes. With no catalyst to anchor the move and minimal time left for momentum to compound, the risk/reward of chasing the downside here is poor. Probability set below 0.5 primarily due to the very short time horizon and the absence of any confirming catalyst.
?Nov 12, 11:40 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down ~2.31% intraday with no news catalyst visible, suggesting this is likely technical or sector-driven selling. The macro context shows T10YIE at 1.7σ below trend (2.2%), which is a low-inflation signal that is generally supportive of long-duration growth stocks like ALGN — this macro backdrop slightly argues against further downside continuation. However, with 245 minutes remaining (a substantial portion of the trading day), there is ample time for the move to extend if institutional selling pressure persists. No reversal signals are explicitly present, and the move is meaningful enough to suggest real conviction by sellers. With no news to fade the move and time remaining, the base case per the system framework is mild continuation. Probability is set conservatively at 0.52 given the macro tailwind that partially offsets the momentum signal — not a high-conviction short, but direction aligns with current flow.
!Nov 12, 11:40 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is down ~2.31% intraday with no news catalyst visible, suggesting this is likely technical or sector-driven selling. The macro context shows T10YIE at 1.7σ below trend (2.2%), which is a low-inflation signal that is generally supportive of long-duration growth stocks like ALGN — this macro backdrop slightly argues against further downside continuation. However, with 245 minutes remaining (a substantial portion of the trading day), there is ample time for the move to extend if institutional selling pressure persists. No reversal signals are explicitly present, and the move is meaningful enough to suggest real conviction by sellers. With no news to fade the move and time remaining, the base case per the system framework is mild continuation. Probability is set conservatively at 0.52 given the macro tailwind that partially offsets the momentum signal — not a high-conviction short, but direction aligns with current flow.
?Nov 12, 10:20 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down 2.44% intraday with no headline catalyst visible, suggesting the move is driven by either sector rotation, broader market pressure, or quiet institutional distribution. The macro context shows T10YIE at 2.2, running 1.7σ below its 24-month trend — a low inflation expectations environment that typically benefits long-duration growth assets like ALGN (a high-multiple med-tech name), which argues slightly against further selling pressure from macro tailwinds. However, that same low-rate read has already been in place and may be priced in. With 325 minutes remaining (effectively a full trading session still ahead), there is ample time for continuation or reversal. The 2.44% move is meaningful and represents real selling flow, but without a news catalyst or clearly supportive sector momentum, the conviction behind continuation is moderate at best. No reversal signals are evident either — no fade off highs back through key levels described. Default momentum bias gives a slight edge to continuation of the down move, but macro context mildly offsets. Assigning a narrow continuation probability just above the 0.5 threshold, consistent with ordinary downside momentum with no strong reason to fade.
!Nov 12, 10:20 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is down 2.44% intraday with no headline catalyst visible, suggesting the move is driven by either sector rotation, broader market pressure, or quiet institutional distribution. The macro context shows T10YIE at 2.2, running 1.7σ below its 24-month trend — a low inflation expectations environment that typically benefits long-duration growth assets like ALGN (a high-multiple med-tech name), which argues slightly against further selling pressure from macro tailwinds. However, that same low-rate read has already been in place and may be priced in. With 325 minutes remaining (effectively a full trading session still ahead), there is ample time for continuation or reversal. The 2.44% move is meaningful and represents real selling flow, but without a news catalyst or clearly supportive sector momentum, the conviction behind continuation is moderate at best. No reversal signals are evident either — no fade off highs back through key levels described. Default momentum bias gives a slight edge to continuation of the down move, but macro context mildly offsets. Assigning a narrow continuation probability just above the 0.5 threshold, consistent with ordinary downside momentum with no strong reason to fade.
❖Nov 10, 4:00 PMnewsvia finnhub
Align Technology to Speak at Upcoming Financial Conference
TEMPE, Ariz., November 10, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at the following financial conference. The presentation will be webcast live via the Investor Relations section of Align's website at h
?Nov 9, 3:31 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 6.01% intraday, which is a significant move representing real institutional flow. However, with only 15 minutes remaining until the forced 3:45 PM ET close, there is very little time for meaningful continuation. At this stage of the session, profit-taking and position squaring into the close dominate, especially after a 6%+ move with no visible catalyst in recent headlines to sustain conviction. The macro context (elevated mortgage rates) is not particularly relevant to ALGN (dental device maker), so no sector tailwind or headwind applies. The core issue is time: 15 minutes is insufficient for a +3% target to be reached on top of an already extended move, and the risk of end-of-day fade on a large unexplained gap is non-trivial. Probability falls below the 0.5 threshold primarily due to time constraints and mean-reversion risk on a large move late in the session.
!Nov 9, 3:31 PMsignalseverity 0.06
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 6.01% intraday, which is a significant move representing real institutional flow. However, with only 15 minutes remaining until the forced 3:45 PM ET close, there is very little time for meaningful continuation. At this stage of the session, profit-taking and position squaring into the close dominate, especially after a 6%+ move with no visible catalyst in recent headlines to sustain conviction. The macro context (elevated mortgage rates) is not particularly relevant to ALGN (dental device maker), so no sector tailwind or headwind applies. The core issue is time: 15 minutes is insufficient for a +3% target to be reached on top of an already extended move, and the risk of end-of-day fade on a large unexplained gap is non-trivial. Probability falls below the 0.5 threshold primarily due to time constraints and mean-reversion risk on a large move late in the session.
✓Nov 9, 9:30 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — pyramid
Pyramid add-on fired at +10.10% unrealized. Added 4 sh @ $167.90 ($671.60). Position now 13 sh @ weighted avg $157.24.
❖Nov 7, 5:14 PMnewsvia finnhub
Did Strong Earnings Just Shift Align's (ALGN) Investment Narrative?
Align Technology reported third quarter 2026 sales of US$1,014.76 million and net income of US$135.04 million, alongside confirming fourth quarter and full year 2026 revenue and GAAP operating margin guidance, while detailing a planned CEO and President handover from Joseph Hogan to healthcare veteran Jennifer Davis from late 2026 into 2027. The business paired that leadership transition with a US$270 million accelerated share repurchase under its existing US$1.0b program and fresh...
✓Nov 6, 3:20 PMdecisionacted
Agent 7 — Day Trader — decide: buy
ALGN is up 2.35% on a meaningful catalyst: a $270M accelerated stock repurchase agreement announced mid-session. ASR programs are genuinely bullish — they signal management confidence and create near-term buying pressure from the repurchase agent. The Extel recognition is minor but reinforces positive sentiment. Macro context (elevated mortgage rates) is not a headwind for ALGN, which operates in dental/orthodontic medtech. However, with only 25 minutes remaining until the forced close, there is limited runway to capture additional upside. The move has likely already priced much of the buyback news, and late-session profit-taking is a real risk. Probability is modestly above 0.5 — the catalyst is real and the sector backdrop is neutral-to-supportive, but the tight time window constrains the continuation thesis.
❖Nov 6, 12:59 PMnewsvia finnhub
Align Technology Recognized in Extel’s 2026 All-America Executive Team Rankings
TEMPE, Ariz. & SAN JOSE, Calif., November 06, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced recognition in the 2026 All-America Executive Team rankings published by Extel Insights (formerly Institutional Investor Research), which evaluates the qua
?Nov 6, 11:11 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 2.62% intraday with 274 minutes remaining (roughly 4.5 hours), suggesting ample time for the move to extend. The magnitude is meaningful and indicates real institutional flow. However, there are no supporting headlines to anchor the catalyst, and the macro context (elevated mortgage rates at 1.9σ above trend) is modestly negative for discretionary/consumer-facing names like ALGN (dental aligners skew toward elective spending). That said, mortgage rates are not a primary driver for ALGN specifically. With no reversal signal indicated, no fade pattern mentioned, and sufficient time remaining, the base case is mild continuation. The setup is ordinary momentum without strong confirmation or strong contradiction — probability sits in the 0.5-0.6 range. Slight lean up given time remaining and meaningful initial move.
!Nov 6, 11:11 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 2.62% intraday with 274 minutes remaining (roughly 4.5 hours), suggesting ample time for the move to extend. The magnitude is meaningful and indicates real institutional flow. However, there are no supporting headlines to anchor the catalyst, and the macro context (elevated mortgage rates at 1.9σ above trend) is modestly negative for discretionary/consumer-facing names like ALGN (dental aligners skew toward elective spending). That said, mortgage rates are not a primary driver for ALGN specifically. With no reversal signal indicated, no fade pattern mentioned, and sufficient time remaining, the base case is mild continuation. The setup is ordinary momentum without strong confirmation or strong contradiction — probability sits in the 0.5-0.6 range. Slight lean up given time remaining and meaningful initial move.
❖Nov 6, 9:10 AMnewsvia finnhub
Align Technology Announces $270 Million Accelerated Stock Repurchase Agreement
TEMPE, Ariz., November 06, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has entered into a new accelerated stock repurchase agreement ("ASR") with Goldman Sachs & Co. LLC ("Goldman Sachs"), to repurchase $270 million of Align’s common sto
❖Nov 6, 5:10 AMnewsvia finnhub
Align Technology Announces $270M Accelerate Buyback Plan
Align Technology, Inc. ("Align") (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™
▢Nov 5, 7:00 PMjournal
Agent 7 — Day Trader opened long 18 @ $163.12
▣Nov 5, 7:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 18 @ $164.28 (+$20.79)
EOD forced close — day trader never carries overnight
?Nov 5, 2:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down 4.33% intraday with no headline catalyst visible, suggesting this is likely driven by technical selling, sector rotation, or broader market flow rather than a specific news event. The move is meaningful in size — consistent with real institutional selling pressure. Macro context (DFF elevated ~2.1σ above trend) suggests tighter financial conditions, which modestly pressures growth/consumer discretionary names like ALGN, offering mild tailwind to the bearish thesis. With 80 minutes remaining, there is enough time for continuation into the close, though not a wide window. No reversal signals are evident from the data provided. The absence of news does not negate momentum — the move itself is the signal. No strong reason to expect a fade (no overbought intraday recovery pattern described, no sector-specific catalyst for reversal). Probability held at modest continuation level given limited confirming evidence beyond the move itself.
!Nov 5, 2:25 PMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
ALGN is down 4.33% intraday with no headline catalyst visible, suggesting this is likely driven by technical selling, sector rotation, or broader market flow rather than a specific news event. The move is meaningful in size — consistent with real institutional selling pressure. Macro context (DFF elevated ~2.1σ above trend) suggests tighter financial conditions, which modestly pressures growth/consumer discretionary names like ALGN, offering mild tailwind to the bearish thesis. With 80 minutes remaining, there is enough time for continuation into the close, though not a wide window. No reversal signals are evident from the data provided. The absence of news does not negate momentum — the move itself is the signal. No strong reason to expect a fade (no overbought intraday recovery pattern described, no sector-specific catalyst for reversal). Probability held at modest continuation level given limited confirming evidence beyond the move itself.
?Nov 5, 11:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down 3.15% with 240 minutes remaining — a meaningful move with substantial time left in the session. No headlines are present to explain the move, which suggests either technical/flow-driven selling or sector rotation. The macro context (DFF elevated 2.1σ above trend) points to a relatively tight monetary environment, which is modestly negative for growth/premium-multiple names like ALGN, though this is not a direct sector catalyst. With 4 hours remaining, there is ample time for continuation if the selling pressure is sustained. However, the absence of a catalyst means this could also be a gap/flush that partially reverses as opportunistic buyers step in. No clear reversal signal is present (no fade off highs back through key levels described), so the base case leans slightly toward continuation. Probability set at 0.52 — a modest lean toward continued downside momentum without strong conviction, reflecting the ambiguity of a news-free move in a macro environment that is mildly unfavorable for the name.
!Nov 5, 11:46 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
ALGN is down 3.15% with 240 minutes remaining — a meaningful move with substantial time left in the session. No headlines are present to explain the move, which suggests either technical/flow-driven selling or sector rotation. The macro context (DFF elevated 2.1σ above trend) points to a relatively tight monetary environment, which is modestly negative for growth/premium-multiple names like ALGN, though this is not a direct sector catalyst. With 4 hours remaining, there is ample time for continuation if the selling pressure is sustained. However, the absence of a catalyst means this could also be a gap/flush that partially reverses as opportunistic buyers step in. No clear reversal signal is present (no fade off highs back through key levels described), so the base case leans slightly toward continuation. Probability set at 0.52 — a modest lean toward continued downside momentum without strong conviction, reflecting the ambiguity of a news-free move in a macro environment that is mildly unfavorable for the name.
❖Nov 5, 5:21 AMnewsvia finnhub
ALIGN TECHNOLOGY INC (NASDAQ:ALGN) Screens as an Undervalued Value Stock
Align Technology looks like a decent value stock: low P/E, no debt, strong profitability, and modest growth, but margin and liquidity risks persist.
✓Nov 4, 11:00 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — pyramid
Pyramid add-on fired at +10.37% unrealized. Added 3 sh @ $163.06 ($489.19). Position now 10 sh @ weighted avg $152.34.
✓Nov 4, 9:36 AMdecisionacted
Agent 7 — Day Trader — decide: buy
ALGN is up nearly 7% intraday, which is a meaningful move reflecting real institutional flow. With 370 minutes remaining (over 6 hours), there is ample time for the move to extend further. No headlines are available to explain the catalyst, but absence of news does not disqualify continuation — large moves without obvious news often reflect earnings pre-announcements, analyst actions, or block positioning. The macro context (DFF elevated 2.1σ above trend) is modestly negative for growth/multiple-expansion names like ALGN (a med-tech/device company), as higher rates pressure valuation. However, this macro headwind is sector-generic and not ticker-specific, and the magnitude of today's move suggests stock-specific positive flow that likely dominates macro noise. No reversal signals are evident from the data provided. The setup is a standard momentum continuation with modest macro headwind — probability set at 0.56, reflecting ordinary momentum with no strong reason to fade but no clear acceleration signal either.
▢Nov 3, 7:00 PMjournal
Agent 7 — Day Trader opened long 18 @ $162.15
▣Nov 3, 7:00 PMjournalstop
Agent 7 — Day Trader closed long 18 @ $159.66 (-$44.82)
Long stop: close $159.66 ≤ stop $159.72
❖Nov 3, 12:33 AMnewsvia finnhub
ALGN Q3 deep dive: product mix, international demand, and new leadership shape outlook
Dental technology company Align Technology (NASDAQ:ALGN) reported Q3 2026 results topping the market’s revenue expectations, with sales up 1.9% year on year to $1.01 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 3.7% below analysts’ estimates. Its non-GAAP profit of $2.80 per share was 1.3% above analysts’ consensus estimates.
❖Nov 2, 4:00 PMnewsvia finnhub
Align Technology Opens 2027 Annual Research Program to Advance Orthodontic and Dental Patient Care
TEMPE, Ariz., November 02, 2026--Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the opening of its 2027 Annual Research Award Program to support clinical and scientific dental research in universities across the globe. This year, up to $300,000 will be awarded to
?Nov 2, 3:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 2.54% with only 5 minutes remaining until the forced close. The move is meaningful and suggests real buying conviction, but with virtually no time left there is almost no runway for further continuation — the position would be flattened almost immediately regardless of outcome. No news catalysts are present, and the macro context (elevated mortgage rates) is not directly relevant to ALGN (dental devices). The momentum is real but time constraint dominates all other factors, making this effectively a coin flip at best. Setting probability at the floor threshold given the time constraint.
!Nov 2, 3:40 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 2.54% with only 5 minutes remaining until the forced close. The move is meaningful and suggests real buying conviction, but with virtually no time left there is almost no runway for further continuation — the position would be flattened almost immediately regardless of outcome. No news catalysts are present, and the macro context (elevated mortgage rates) is not directly relevant to ALGN (dental devices). The momentum is real but time constraint dominates all other factors, making this effectively a coin flip at best. Setting probability at the floor threshold given the time constraint.
?Nov 2, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 2.19% with 355 minutes remaining (effectively most of the trading day still ahead), giving ample time for continuation. The move is meaningful — above 2% suggests real institutional flow or a catalyst not captured in headlines. Absence of news is not disqualifying per the framework. However, there are limiting factors: (1) macro context shows mortgage rates elevated at 7.24%, 2.3σ above trend — ALGN (dental devices/orthodontics) is not directly in the reactive sectors listed, but elevated rates broadly compress consumer discretionary spending, which is a mild headwind for elective dental procedures; (2) no corroborating news to anchor the move means it could be technical or short-covering, which can fade; (3) the move has not yet reached the +3% profit target threshold, leaving room to run. On balance, the momentum is real and time remaining is substantial, but the macro consumer spending headwind and lack of a confirmed catalyst keep conviction moderate. Assigning a slight edge to continuation without strong conviction.
!Nov 2, 9:51 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 2.19% with 355 minutes remaining (effectively most of the trading day still ahead), giving ample time for continuation. The move is meaningful — above 2% suggests real institutional flow or a catalyst not captured in headlines. Absence of news is not disqualifying per the framework. However, there are limiting factors: (1) macro context shows mortgage rates elevated at 7.24%, 2.3σ above trend — ALGN (dental devices/orthodontics) is not directly in the reactive sectors listed, but elevated rates broadly compress consumer discretionary spending, which is a mild headwind for elective dental procedures; (2) no corroborating news to anchor the move means it could be technical or short-covering, which can fade; (3) the move has not yet reached the +3% profit target threshold, leaving room to run. On balance, the momentum is real and time remaining is substantial, but the macro consumer spending headwind and lack of a confirmed catalyst keep conviction moderate. Assigning a slight edge to continuation without strong conviction.
❖Nov 2, 9:43 AMnewsvia finnhub
Global Orthodontic Braces Market Size, Share, and Forecast Report 2026-2031 Featuring Profiles of Dentsply Sirona, Align Technology, Straumann, Envista, 3M, Henry Schein, and American Orthodontics
Capitalize on clear aligners, adult orthodontics, AI-driven personalization and direct-to-consumer care through targeted innovation and digital accessDublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Orthodontic Braces Market (2026 Edition)" has been added to ResearchAndMarkets.com's offering. The global orthodontic braces market is positioned for substantial expansion as demand for dental aesthetics, corrective orthodontic treatment and personalized care continues to increase. The report provides a co
❖Oct 31, 3:23 PMnewsvia finnhub
5 insightful analyst questions from Align Technology’s Q3 earnings call
Align Technology’s third quarter results were shaped by a combination of resilient Clear Aligner demand and shifts in product mix, particularly toward lower-priced scanner configurations. Management cited record doctor participation and increased shipments among both orthodontists and general practitioners, along with expanding international growth as key drivers. CEO Joe Hogan highlighted that, despite a challenging environment for discretionary dental spending, “record doctor submitters” and i
❖Oct 30, 6:19 PMnewsvia finnhub
Align Technology (ALGN) Stock Sees Modest Fair Value Cut As Analyst Views Split
Align Technology’s modeled fair value has been trimmed from US$199.21 to US$188.86, pointing to a more conservative price target in the latest update. This shift lines up with research that shows analysts reducing targets while staying split between those who still see upside potential and those who are more cautious on demand trends and valuation drivers. As you read on, you will see how these changes fit into the evolving narrative around Align Technology and what to watch next. Analyst...
❖Oct 30, 12:11 PMnewsvia finnhub
1 profitable stock on our watchlist and 2 facing headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
❖Oct 30, 10:11 AMnewsvia finnhub
Align Technology: The Competitive Threat Has Eased, But Growth Remains A Concern
Align Technology faces new catalysts, developments, and litigation progress that shift the investment landscape. I rate ALGN stock as Buy. Click to read my full update.
❖Oct 30, 2:40 AMnewsvia finnhub
Align Technology: More iTero Installations, Lower Scanner Revenue
Align Technology, Inc. is downgraded from buy to hold with a $150 target price, reflecting limited upside. Read more on ALGN stock here.
❖Oct 29, 11:06 AMnewsvia finnhub
ALGN Q3 Earnings & Revenues Beat, '26 Sales View Down, Stock Falls
Align Technology's Q3 earnings and revenues beat estimates on higher aligner shipments, but a lowered 2026 sales outlook weighs on shares.
?Oct 29, 9:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down -1.65% following Q3 2026 earnings call materials published overnight/this morning. The move is modest but directionally meaningful — earnings disappointment or cautious guidance is the likely catalyst. With 360 minutes remaining (full trading day essentially), there is ample time for continuation if sellers remain in control. However, a -1.65% move post-earnings is relatively contained, suggesting the initial reaction may already be partially digested or that results were mixed rather than clearly negative. The macro context (T10Y2Y at 1.7σ below trend, modest curve flattening) is mildly unhelpful for growth/medtech names like ALGN but not a strong headwind. Post-earnings drift tends to persist intraday when the move is driven by fundamental re-rating, but the modest magnitude here reduces conviction. No reversal pattern is evident from the data provided. On balance, slight lean toward continuation given earnings-driven flow and time remaining, but confidence is low — probability sits just above the 0.5 threshold.
!Oct 29, 9:46 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is down -1.65% following Q3 2026 earnings call materials published overnight/this morning. The move is modest but directionally meaningful — earnings disappointment or cautious guidance is the likely catalyst. With 360 minutes remaining (full trading day essentially), there is ample time for continuation if sellers remain in control. However, a -1.65% move post-earnings is relatively contained, suggesting the initial reaction may already be partially digested or that results were mixed rather than clearly negative. The macro context (T10Y2Y at 1.7σ below trend, modest curve flattening) is mildly unhelpful for growth/medtech names like ALGN but not a strong headwind. Post-earnings drift tends to persist intraday when the move is driven by fundamental re-rating, but the modest magnitude here reduces conviction. No reversal pattern is evident from the data provided. On balance, slight lean toward continuation given earnings-driven flow and time remaining, but confidence is low — probability sits just above the 0.5 threshold.
❖Oct 29, 9:24 AMnewsvia finnhub
Morgan Stanley Maintains Equal-Weight on Align Technology, Lowers Price Target to $175
Morgan Stanley analyst Erin Wright maintains Align Technology (NASDAQ:ALGN) with a Equal-Weight and lowers the price target from $188 to $175.
❖Oct 29, 8:30 AMnewsvia finnhub
Align Technology, Inc. Q3 2026 Earnings Call Summary
Moby summary of Align Technology, Inc.'s Q3 2026 earnings call
❖Oct 29, 1:29 AMnewsvia finnhub
Align (ALGN) Q3 2026 Earnings Call Transcript
Record doctor submitters and aligner growth offset softer consumer spending headwinds.
❖Oct 28, 10:04 PMnewsvia finnhub
Align Technology Q3 Earnings Call Highlights
Align Technology (NASDAQ:ALGN) reported third-quarter 2026 revenue of $1.015 billion, up 1.9% from a year earlier, as higher clear aligner volumes and international growth helped offset continued pressure in discretionary dental spending and capital-equipment purchasing. Clear aligner shipments inc
❖Oct 28, 6:00 PMnewsvia finnhub
Align Technology, Inc. (ALGN) Q3 2026 Earnings Call Transcript
Align Technology, Inc. (ALGN) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDTCompany ParticipantsShirley Stacy - Vice President of Corporate...
❖Oct 28, 5:11 PMnewsvia finnhub
Align Technology (NASDAQ:ALGN) Posts In-Line Q3 Results but Q4 Guidance Trails Consensus
Align Tech Q3 2026 results met estimates, but soft Q4 revenue guidance and steady Clear Aligner growth keep focus on margins and buybacks.
❖Oct 28, 5:09 PMnewsvia finnhub
Align Technology (NASDAQ:ALGN) beats Q3 2026 sales expectations but quarterly revenue guidance misses expectations
Dental technology company Align Technology (NASDAQ:ALGN) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 1.9% year on year to $1.01 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 3.7% below analysts’ consensus estimates. Its non-GAAP profit of $2.80 per share was 1.3% above analysts’ consensus estimates.
❖Oct 28, 4:30 PMnewsvia finnhub
Compared to Estimates, Align Technology (ALGN) Q3 Earnings: A Look at Key Metrics
The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
❖Oct 28, 4:20 PMnewsvia finnhub
Align Technology (ALGN) Beats Q3 Earnings and Revenue Estimates
Align Technology (ALGN) delivered earnings and revenue surprises of +1.45% and +1.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
❖Oct 28, 4:11 PMnewsvia finnhub
Align Technology: Q3 Earnings Snapshot
(ALGN) on Wednesday reported third-quarter earnings of $135 million.On a per-share basis, the Tempe, Arizona-based company said it had profit of $1.
❖Oct 28, 4:05 PMnewsvia finnhub
Align Technology Announces Third Quarter 2026 Financial Results
TEMPE, Ariz., October 28, 2026--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the third quarter ("Q3'26").
❖Oct 28, 4:05 PMnewsvia finnhub
Align Technology Announces CEO Succession Plan
TEMPE, Ariz., October 28, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors ("Board") has appointed Jennifer L. Davis as the Company’s next President and Chief Executive Officer, effective December 31, 2026. Davis will succee
❖Oct 28, 1:49 PMnewsvia finnhub
Align Technology Q3 2026 Earnings Call Transcript
Align Technology (NASDAQ:ALGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
❖Oct 28, 1:02 PMnewsvia finnhub
Align Technology, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-10-28. The following slide deck was published by Align Technology, Inc.
❖Oct 28, 12:11 PMnewsvia finnhub
Align Technology Sees Q4 Sales $1.000B-$1.020B vs $1.048B Est
Align Technology (NASDAQ:ALGN) sees Q4 sales of $1.000 billion-$1.020 billion vs $1.048 billion analyst estimate.
❖Oct 28, 12:03 PMnewsvia finnhub
Align Tech Q3 Adj. EPS $2.80 Beats $2.78 Estimate, Sales $1.015B Beat $1.005B Estimate
Align Tech (NASDAQ:ALGN) reported quarterly earnings of $2.80 per share which beat the analyst consensus estimate of $2.78 by 0.72 percent. This is a 7.28 percent increase over earnings of $2.61 per share from the same
❖Oct 27, 2:08 PMnewsvia finnhub
Align Technology (ALGN) Heads Into Earnings As Undervalued Case Faces A Fresh Test
Align Technology (ALGN) heads into its upcoming third quarter earnings report with traders bracing for a sizeable move, as options pricing signals elevated volatility and recent operating trends remain mixed. Over the past year, Align Technology has delivered a 12.24% total shareholder return, even as the 90 day share price return declined 13.29%. The recent 7 day and 30 day share price gains hint at rebuilding momentum ahead of earnings and follow its fresh commitment to orthodontic research...
❖Oct 27, 8:38 AMnewsvia finnhub
What to expect from Align Technology’s (ALGN) Q3 earnings
Dental technology company Align Technology (NASDAQ:ALGN) will be announcing earnings results this Wednesday after market close. Here’s what you need to know.
❖Oct 27, 7:58 AMnewsvia finnhub
Is the Options Market Predicting a Spike in Align Technology Stock?
Investors need to pay close attention to ALGN stock based on the movements in the options market lately.
❖Oct 26, 9:00 AMnewsvia finnhub
Align Technology Commits Additional $1 Million to the American Association of Orthodontists Foundation to Support the Next Generation of Orthodontic Educators and Leaders
TEMPE, Ariz., October 26, 2026--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced a new $1 million, five-year commitment to the American Association of Orthodontists (AAO) Foundation building on the Company’s most recent $1 million pledge made in 2021. The commitment
❖Oct 25, 11:51 AMnewsvia finnhub
Invisalign’s Moment of Truth: Will International Growth Save ALGN on Oct 28?
Align Technology (NASDAQ:ALGN) reports third-quarter results on October 28. North America is flat and scanner revenue is shrinking, so I’ll be watching whether double-digit international aligner growth can keep the Invisalign story moving. Record Aligner Volumes Meet Shrinking Scanner Sales In Q2, Align shipped a record 691.8K Clear Aligner cases, +7.4% YoY. Revenue reached $1.056B […]
❖Oct 22, 8:08 AMnewsvia finnhub
Align Technology to Report Q3 Earnings: What's in the Cards?
ALGN's Q3 earnings may benefit from Clear Aligner growth and digital innovations, while capital equipment market challenges could weigh on results.
❖Oct 22, 3:52 AMnewsvia finnhub
Mizuho Maintains Outperform on Align Technology, Lowers Price Target to $200
Mizuho analyst Steven Valiquette maintains Align Technology (NASDAQ:ALGN) with a Outperform and lowers the price target from $220 to $200.
?Oct 21, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 1.59% with 320 minutes remaining — well short of the 2-5% threshold that would signal high-conviction institutional flow, but a solid positive drift nonetheless. No news catalyst is present, which is neutral per guidance. The macro context is mildly negative for ALGN: 2Y yields printing 2.1σ above trend at 4.77% creates headwinds for long-duration growth/tech-adjacent names like ALGN (a high-multiple medical device company), as elevated rates pressure DCF valuations and can attract rotation out of growth. This is a real but not overwhelming fade signal — it argues modestly against continuation rather than strongly for reversal. Time remaining is ample (320 minutes), so there is room for the move to extend. Balancing the moderate upward momentum against the rate headwind and absence of a clear catalyst, I lean slightly toward continuation but without conviction. This sits at the low end of the trade-triggering range.
!Oct 21, 10:25 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 1.59% with 320 minutes remaining — well short of the 2-5% threshold that would signal high-conviction institutional flow, but a solid positive drift nonetheless. No news catalyst is present, which is neutral per guidance. The macro context is mildly negative for ALGN: 2Y yields printing 2.1σ above trend at 4.77% creates headwinds for long-duration growth/tech-adjacent names like ALGN (a high-multiple medical device company), as elevated rates pressure DCF valuations and can attract rotation out of growth. This is a real but not overwhelming fade signal — it argues modestly against continuation rather than strongly for reversal. Time remaining is ample (320 minutes), so there is room for the move to extend. Balancing the moderate upward momentum against the rate headwind and absence of a clear catalyst, I lean slightly toward continuation but without conviction. This sits at the low end of the trade-triggering range.
❖Oct 21, 9:00 AMnewsvia finnhub
Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
❖Oct 21, 6:37 AMnewsvia finnhub
Piper Sandler Maintains Overweight on Align Technology, Lowers Price Target to $205
Piper Sandler analyst Jason Bednar maintains Align Technology (NASDAQ:ALGN) with a Overweight and lowers the price target from $235 to $205.
❖Oct 20, 5:02 AMnewsvia finnhub
Global Clear Aligners Market Size, Share, Trends, and Forecast to 2031 | Image-Conscious Adults Set to Nearly Double the Clear Aligner Market to $11bn Market Value
New Report values clear aligners market at $6.09bn in 2026, with dental service organisations and digital orthodontics widening access — though cut-price direct-to-consumer rivals and complex cases test Align Technology, Straumann, Dentsply Sirona and EnvistaDublin, Oct. 20, 2026 (GLOBE NEWSWIRE) -- "Clear Aligners Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Global Clear Aligners Market to Reach USD 11.04 Billion by 2031 The global clear aligners market
❖Oct 20, 3:38 AMnewsvia finnhub
What You Need To Know Ahead of Align Technology's Earnings Release
Align Technology is scheduled to report its third-quarter results later this month, and analysts expect a double-digit earnings increase.
❖Oct 16, 9:11 PMnewsvia finnhub
Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent Court
SAN JOSE, Calif. & TEMPE, Ariz., October 17, 2026--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court ("UPC") finding that aligner systems incorporating Angelalign’s Torque Ridges feature infringe Align’s European Patent EP 2 237 738 B1, which relates to Align’s Power Ridge® technology.
?Oct 16, 2:21 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down ~1.96% today with no attributable headline catalyst, suggesting this is either technical selling or broader market pressure. The move is meaningful but sits just at the lower boundary of the 2-5% 'conviction' range. Macro context is elevated mortgage rates (7.4%, +3.3σ above trend), which primarily pressures homebuilders, REITs, and banks — ALGN as a dental device/orthodontics company has minimal direct sensitivity to mortgage rates, so no tailwind or headwind from that factor. With 85 minutes remaining there is reasonable runway for continuation if momentum persists, but the absence of a specific catalyst makes a sustained flush less likely than if there were a news-driven dislocation. No reversal signals are explicitly present, so there is no strong reason to expect a fade either. This is a borderline read: momentum is modestly negative, time is adequate, macro is sector-neutral for ALGN, and no news disrupts the thesis. Assigning 0.50 — the minimum threshold — reflecting a coin-flip lean toward continuation given the system's bounded risk profile and the instruction to favor action on borderline reads.
!Oct 16, 2:21 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is down ~1.96% today with no attributable headline catalyst, suggesting this is either technical selling or broader market pressure. The move is meaningful but sits just at the lower boundary of the 2-5% 'conviction' range. Macro context is elevated mortgage rates (7.4%, +3.3σ above trend), which primarily pressures homebuilders, REITs, and banks — ALGN as a dental device/orthodontics company has minimal direct sensitivity to mortgage rates, so no tailwind or headwind from that factor. With 85 minutes remaining there is reasonable runway for continuation if momentum persists, but the absence of a specific catalyst makes a sustained flush less likely than if there were a news-driven dislocation. No reversal signals are explicitly present, so there is no strong reason to expect a fade either. This is a borderline read: momentum is modestly negative, time is adequate, macro is sector-neutral for ALGN, and no news disrupts the thesis. Assigning 0.50 — the minimum threshold — reflecting a coin-flip lean toward continuation given the system's bounded risk profile and the instruction to favor action on borderline reads.
?Oct 15, 3:36 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is up 3.18% today with no headline catalyst identified, suggesting this may be technical or flow-driven. However, with only 10 minutes remaining until the forced close, there is minimal time for the move to extend further. At this stage of the session, profit-taking and position squaring typically dominate, especially on a move of this magnitude without a clear fundamental driver. The macro context (elevated mortgage rates at 3.3σ above trend) is not directly relevant to ALGN (dental devices/orthodontics), so it neither supports nor undermines the move. The combination of very little time remaining and no clear continuation catalyst pushes the probability below 0.5. The risk is that this move has already run its course and late-session selling into the close is more likely than further extension.
!Oct 15, 3:36 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
ALGN is up 3.18% today with no headline catalyst identified, suggesting this may be technical or flow-driven. However, with only 10 minutes remaining until the forced close, there is minimal time for the move to extend further. At this stage of the session, profit-taking and position squaring typically dominate, especially on a move of this magnitude without a clear fundamental driver. The macro context (elevated mortgage rates at 3.3σ above trend) is not directly relevant to ALGN (dental devices/orthodontics), so it neither supports nor undermines the move. The combination of very little time remaining and no clear continuation catalyst pushes the probability below 0.5. The risk is that this move has already run its course and late-session selling into the close is more likely than further extension.
❖Oct 15, 8:10 AMnewsvia finnhub
Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More
Pre-Market Stock Futures: Futures are trading mixed, but the Nasdaq is down sharply Thursday morning as worries about AI overspending continue to emerge. Wall Street’s worst fears materialized yesterday, as the Consumer Price Index (CPI) report came in above expectations, with energy prices as a major factor. This will, of course, change the narrative on […]
❖Oct 15, 4:31 AMnewsvia finnhub
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
❖Oct 15, 4:00 AMnewsvia finnhub
This Align Technology Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Analysts downgraded Envista, Cirrus Logic, ZTO Express, Align Technology and Par Pacific, with mixed price-target changes.
❖Oct 15, 2:23 AMnewsvia finnhub
Baird Downgrades Align Technology to Neutral, Lowers Price Target to $162
Baird analyst Jeff Johnson downgrades Align Technology (NASDAQ:ALGN) from Outperform to Neutral and lowers the price target from $218 to $162.
?Oct 14, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 14, 6:02 PMsignalseverity 0.11
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
❖Oct 14, 6:10 AMnewsvia finnhub
U.S. Digital Dentistry Market to Top $1.6B by 2032 as Clear Aligners and DSOs Drive Intraoral Scanner and 3D Printer Adoption
Report Ranks Dentsply Sirona, Align Technology and Ivoclar, With Unit Sales, Average Selling Prices and 2025 Market Share as Low-Cost Entrants Push Prices DownDublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Digital Dentistry Market Size, Share & Trends Analysis | United States | 2026-2032 | Includes: CAD/CAM Devices, CAD/CAM Materials, Dental 3D Printers, and 2 more" has been added to ResearchAndMarkets.com's offering. The U.S. digital dentistry market was valued at approximately $1.2 billion in 2025
?Oct 13, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 13, 6:02 PMsignalseverity 0.12
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Oct 12, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 12, 6:02 PMsignalseverity 0.14
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Oct 9, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 9, 6:01 PMsignalseverity 0.12
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
❖Oct 9, 5:11 AMnewsvia finnhub
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.
❖Oct 9, 3:46 AMnewsvia finnhub
Stifel Maintains Buy on Align Technology, Lowers Price Target to $175
Stifel analyst Jonathan Block maintains Align Technology (NASDAQ:ALGN) with a Buy and lowers the price target from $210 to $175.
?Oct 8, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 8, 6:02 PMsignalseverity 0.13
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Oct 7, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 7, 6:02 PMsignalseverity 0.14
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Oct 6, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 6, 6:02 PMsignalseverity 0.13
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Oct 5, 6:21 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path traces a persistent down-and-left drift from $153.49 on 2026-09-08 to $140.65 on 2026-10-05, with closes making lower highs and lower lows across the full window. Down-day volume dominates throughout: notably 2026-09-08 (807K, -3.25%), 2026-09-15 (1.0M, -3.92%), 2026-09-18 (1.5M, -1.40%), 2026-09-23 (1.3M, -3.34%), and today's 1.7M on a -2.15% close — while the strongest up-day of the period (2026-09-22, +4.36% on 967K) failed to recover prior highs and was immediately reversed on heavy volume the next session. Today's bar punctuates the pattern decisively: a volume z-score of 3.45 (1.7M vs. 903K ADV) on a down-close break to a new 20-day closing low of $140.65 satisfies all three bearish criteria — (1) volume is 1.88× ADV on a price extreme (new low), (2) the last three sessions (2026-10-01 flat/620K → 2026-10-02 -1.11%/550K → 2026-10-05 -2.15%/1.7M) show net negative price movement on sharply expanding volume, and (3) the overall 20-day path exhibits a clear down-and-right drift. The SIR path unambiguously reflects sellers in control. Risks: A reclaim of the $145–$146 band (the late-September consolidation zone around 2026-09-25 to 2026-09-30) on volume exceeding today's 1.7M would invalidate the distribution read and suggest a climax-reversal rather than continuation. Additionally, the elevated 5-year inflation breakeven (T5YIFR at 1.8σ above trend as of 2026-10-02) could reverse sharply on a macro catalyst, compressing real yields and lifting rate-sensitive Health Care names like ALGN indiscriminately.
?Oct 5, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 5, 6:02 PMsignalseverity 0.14
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
✓Oct 5, 9:45 AMdecisionacted
Agent 7 — Day Trader — decide: buy
ALGN is down ~2.79% on a clear catalyst: an Evercore ISI downgrade reported this morning. Analyst downgrades from a respected firm like Evercore ISI tend to generate sustained selling pressure throughout the session as institutional holders reassess positions and sell-side desks distribute. The move is meaningful in magnitude and has a clean fundamental driver, suggesting it is not noise. Macro context adds a mild headwind — 5-year forward inflation expectations are elevated (1.8σ above trend), which pressures rate-sensitive and growth-oriented names like ALGN that rely on consumer discretionary spending and carry a growth multiple. With 360 minutes remaining there is ample time for the move to extend further into the close. No reversal signals are evident from the data provided — the stock appears to be trending steadily lower rather than showing a morning spike/fade pattern. The downgrade catalyst is likely to continue attracting incremental sellers who missed the initial print. Balancing all factors: clear negative catalyst, supportive macro headwind for a growth/consumer name, and plenty of session time remaining argue for continuation probability modestly above the baseline.
▢Oct 4, 8:00 PMjournal
Agent 7 — Day Trader opened short 21 @ $139.73
▣Oct 4, 8:00 PMjournalstop
Agent 7 — Day Trader closed short 21 @ $141.97 (-$47.04)
Short stop: close $141.97 ≥ stop $141.83
?Oct 2, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 2, 6:02 PMsignalseverity 0.12
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Oct 1, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Oct 1, 6:02 PMsignalseverity 0.12
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Sep 30, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Sep 30, 6:02 PMsignalseverity 0.16
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Sep 28, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Sep 28, 6:01 PMsignalseverity 0.20
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Sep 28, 9:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down 1.66% intraday, which is a modest move — not yet at the 2-5% threshold that would indicate strong conviction flow. The sole headline is actually bullish (undervalued value stock, strong profits, no debt), which creates a mild headwind against continuation of the downside move and raises the probability of a mean-reversion bid into the close. Macro context shows 5Y5Y inflation forwards elevated at 1.7σ above trend — rate-sensitive pressure is real but ALGN is not a pure rate-sensitive name; it's a med-tech growth stock where the effect is indirect. With 355 minutes remaining (essentially a full session still ahead), there is ample time for either continuation or reversal, but the bullish headline framing and modest move magnitude together suggest the selling pressure may not have strong legs. The setup does not meet the 0.5 threshold for a continuation trade given the counteracting bullish catalyst and the relatively contained move size.
!Sep 28, 9:50 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ALGN is down 1.66% intraday, which is a modest move — not yet at the 2-5% threshold that would indicate strong conviction flow. The sole headline is actually bullish (undervalued value stock, strong profits, no debt), which creates a mild headwind against continuation of the downside move and raises the probability of a mean-reversion bid into the close. Macro context shows 5Y5Y inflation forwards elevated at 1.7σ above trend — rate-sensitive pressure is real but ALGN is not a pure rate-sensitive name; it's a med-tech growth stock where the effect is indirect. With 355 minutes remaining (essentially a full session still ahead), there is ample time for either continuation or reversal, but the bullish headline framing and modest move magnitude together suggest the selling pressure may not have strong legs. The setup does not meet the 0.5 threshold for a continuation trade given the counteracting bullish catalyst and the relatively contained move size.
?Sep 25, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
!Sep 25, 6:02 PMsignalseverity 0.19
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Sep 24, 1:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ALGN is down 1.68% today, which is a modest but real intraday move. However, several factors weigh against continuation into the close. The macro context is notable: 5Y5Y forward inflation expectations are running 2.0σ above trend, which typically pressures rate-sensitive and growth equities — ALGN, as a premium medical device/consumer discretionary name, can be sensitive to rate sentiment, which is a mild headwind favoring continued selling. However, the move at -1.68% is below the 2-5% threshold that would itself constitute strong directional evidence. With 120 minutes remaining there is time for continuation, but without a news catalyst or clear volume confirmation, this looks more like drift than conviction selling. No headlines are present to anchor a thesis. The inflation print could be the catalyst, but it's sector-broad rather than ALGN-specific. Given the modest magnitude of the move, absence of confirming news, and macro tailwind that could support further selling but is diffuse, the balance of evidence does not clearly support continuation — the risk of a mean-reversion into close is roughly equal or slightly dominant. Probability falls just below the 0.5 threshold.
✓Sep 24, 7:04 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
ALGN is down 18.7% from its 30-day high with no identifiable fundamental catalyst — no negative news headlines, no insider selling, and the SEC filings lack disclosed adverse metrics, suggesting the drop is macro/sector-driven rather than company-specific impairment. The options flow is a meaningful positive signal: unusual call volume (z=2.21) with a low P/C ratio of 0.41 on the most recent trading day implies informed bullish positioning into the dip. Earnings are 34 days out, which is beyond the imminent threshold and not a near-term binary veto; the $2.90 consensus EPS provides a near-term fundamental anchor.
?Sep 23, 6:21 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path traces a clear down-and-right drift: ALGN opened the window near $159 (2026-08-26) and closes today at $148.17, a ~7% decline across the period, while the heaviest volume sessions are predominantly down-days. The three most consequential volume spikes — 2026-08-31 (1.3M, +1.40%), 2026-09-18 (1.5M, -1.40%), and today 2026-09-23 (1.3M, -3.34%) — show a deteriorating pattern: the lone high-volume up-day (Aug 31) could not sustain price, while the two largest-volume sessions in the second half of the window are both down-days with meaningful losses. Most tellingly, yesterday's 4.36% gap-up on only 940K volume (below ADV of 890K… actually near it) was immediately reversed today on 1.3M (z-score +1.89), confirming that sellers absorbed the bounce aggressively — a textbook distribution tell in 2-D PV space. Risks: The macro context flags elevated inflation expectations (T5YIFR at 2.34, 1.7σ above trend), which is a rate-sensitive headwind reinforcing the bearish read; however, this call would be invalidated if ALGN reclaims and closes above the $153–$154 resistance zone (the early-September cluster) on volume materially above 1.0M, signaling genuine demand re-entry and breaking the distribution path.
?Sep 23, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down 18.7% from its 30-day high, but there are no company-specific negative headlines, guidance cuts, or accounting concerns in the evidence window to explain the drop — suggesting macro or sector rotation is the primary driver. The macro context shows the 5-year forward inflation rate at 1.7σ above trend, which pressures rate-sensitive and growth-oriented equities like ALGN (a high-multiple medtech/consumer discretionary name), and this is a meaningful headwind. With no SEC filing metrics available to confirm current financial health and no news to provide a catalyst for recovery, conviction in a near-term rebound is limited but the company's historical fundamentals remain reasonably solid.
?Sep 23, 4:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 23, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 23, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 23, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 23, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 23, 11:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 23, 10:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 23, 7:00 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
?Sep 22, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ALGN is down ~15.9% from its 30-day high, but there are no company-specific negative catalysts visible in the recent news or SEC filings — the 8-K and 10-Q filings lack reported metrics suggesting a major guidance cut or deterioration event. However, the macro backdrop is a meaningful headwind: the 5-year forward inflation rate (T5YIFR) is running 1.9σ above its 24-month trend, pressuring rate-sensitive and discretionary/premium consumer sectors like dental aligners. The single news headline carries near-neutral sentiment (0.10), and the lack of strong bullish catalysts tempers conviction on a near-term rebound.
?Sep 22, 4:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ALGN is down 18.1% from its 30-day high with no confirming headlines, SEC filing metrics, or insider activity to explain the drop — suggesting a macro/sector-driven or sentiment-driven move rather than a confirmed fundamental impairment. Health Care sector is showing relative strength (rank 3/11, +1.23pts vs SPY over 30d), which is a mild positive for sector tailwinds, but ALGN dipping while the sector outperforms points to idiosyncratic pressure. Options flow is neutral-to-mildly bearish (P/C 0.83, put z-score slightly elevated at 0.88), offering no strong confirmation of informed buying. Earnings are 50 days out (non-factor), and VIX is benign at 14.32.
▣May 19, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.28 (-$296.15)
Stop: premium $2.28 ≤ trailing floor $3.94 (peak $5.25 × 0.75)
▢May 18, 8:00 PMjournal
options_momentum opened long 100 @ $5.24

← Back to dashboard